After purchasing this CME Certification, you will receive a PDF download in your email containing the article and the evaluation. If you do not receive it, please check your spam box or contact kristy@acro.org.
The article, “ACROPath Oligometastases: The American College of Radiation Oncology Clinical Pathway” has been approved for 1 AMA PRA Category 1 credit. TM
Target Audience:
Physicians (M.D. and D.O.) needing credit for relicensure or initial licensure.
Learning Objectives:
- Understand the rationale and evidence supporting metastasis-directed radiotherapy for patients with oligometastatic disease, including survival benefits and cost-effectiveness.
- Explain the clinical and radiographic criteria used to define oligometastatic disease and how they inform treatment selection.
- Apply the ACROPath treatment-recommendation framework to determine personalized radiotherapy strategies based on primary tumor histology, metastatic site, efficacy, toxicity, and resource‐availability.
Date Credit Expires: 11/17/2027
Faculty Disclosure Information:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Miami-Dade County Medical Association and the American College of Radiation Oncology. The Miami-Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians.
The Miami-Dade County Medical Association designates this activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
None of the planners or faculty of this activity had any financial relationships to disclose except for Christopher Jahraus who disclosed he’s a consultant for RADformation, has other financial/material support from Klarity (Expert Witness), is a stock owner/investor in the privately held company Fuse Oncology, and is an advisory board member for Elekta. Paul Wallner disclosed he is an employee/owner of Genesiscare USA, a consultant for Health Management Associates, and an Advisory Board Member/has other financial/material support from Nanocan Therapeutics, Inc. Steven Finkelstein disclosed he’s on the speaker's bureau for Myriad JJ, is an advisory board member for Lantheas, Blue Earth, Bayer, Novartis, Myriad, & JJ. Bridget Koontz disclosed grant/research support with NCI (U10CA180868), is a stock owner/investor, for the privately held company Rythera Therapeutics, is an advisory board member with FUSE Oncology, Novartis, Myriad Genetics (which has ended). All of the financial relationships identified for these planners and faculty have been mitigated.
Questions:
If you have any questions, please contact Kristy Williford.
Print Page